Haemophilia

Papers
(The TQCC of Haemophilia is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
WFH Guidelines for the Management of Hemophilia, 3rd edition938
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A63
The role of telemedicine in the delivery of health care in the COVID‐19 pandemic53
The World Federation of Hemophilia Annual Global Survey 1999‐201849
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US39
Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring37
Synovitis and synovectomy in haemophilia33
Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC31
Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia30
World Federation of Hemophilia Gene Therapy Registry30
Telehealth for delivery of haemophilia comprehensive care during the COVID‐19 pandemic29
Low immunogenicity of emicizumab in persons with haemophilia A28
Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study28
Genetic causes of haemophilia in women and girls28
Physiotherapy interventions for pain management in haemophilia: A systematic review27
European principles of care for women and girls with inherited bleeding disorders27
Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns27
Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management27
Women and girls with haemophilia: Lessons learned26
Emicizumab state‐of‐the‐art update26
Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A25
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study25
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate)24
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data24
Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?23
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study23
Evidence of a disability paradox in patient‐reported outcomes in haemophilia23
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays23
Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel23
Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature22
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies22
The Function of extravascular coagulation factor IX in haemostasis21
Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery21
Haemophilia care in China: Achievements in the past decade20
Delivering on the promise of gene therapy for haemophilia20
Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A20
Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and19
WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia19
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays19
An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia19
Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?19
Non‐severe haemophilia: Is it benign? – Insights from the PROBE study18
Laboratory issues in gene therapy and emicizumab18
Registry of patients with congenital bleeding disorders and COVID‐19 in Madrid17
How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types17
von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis17
Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real‐world cases to support shared decision‐making17
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies17
The 2021 von Willebrand disease guidelines: Clarity and controversy16
Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS16
Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors16
Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review16
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update16
Invasive procedures in patients with haemophilia: Review of low‐dose protocols and experience with extended half‐life FVIII and FIX concentrates and non‐replacement therapies16
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study16
Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States16
Hemophilia gene therapy—New country initiatives15
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice15
Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study15
Physical activity levels in men with Haemophilia—A single centre UK survey15
In‐hospital management of persons with haemophilia and COVID‐19: Practical guidance15
Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment15
Effectiveness of monthly low dose emicizumab prophylaxis without 4‐week loading doses among patients with haemophilia A with and without inhibitors: A case series report14
Comparative analysis of the pivotal studies of extended half‐life recombinant FVIII products for treatment of haemophilia A14
Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis14
An exploration of why men with severe haemophilia might not want gene therapy: The exigency study14
Management of pregnancy in women with factor VII deficiency: A case series14
Gene therapy: Practical aspects of implementation14
Use of ultrasound for assessment of musculoskeletal disease in persons with haemophilia: Results of an International Prophylaxis Study Group global survey14
Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU13
Managing women‐specific bleeding in inherited bleeding disorders: A multidisciplinary approach13
Diagnosis of von Willebrand disease: An assessment of the quality of testing in North American laboratories13
Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study13
Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti–factor XIII autoantibodies13
Management of COVID‐19‐associated coagulopathy in persons with haemophilia13
Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A13
Parental perspectives on gene therapy for children with haemophilia: The Exigency study13
Efficacy and safety of fibrinogen concentrate for on‐demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency13
Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long‐term experience at a single Haemophilia centre13
Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise12
The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assays12
Real‐world analysis of haemophilia patients in China: A single centre's experience12
Detection and evaluation of haemophilic arthropathy: Which tools may be considered more reliable12
Gaining more insight into ankle pain in haemophilia: A study exploring pain, structural and functional evaluation of the ankle joint12
The relationship between chronic pain and psychosocial aspects in patients with haemophilic arthropathy. A cross‐sectional study12
Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review12
The B‐Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B12
POSTER ABSTRACTS12
Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India12
Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study12
Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States12
Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls12
Feasibility and outcomes of low‐dose and low‐frequency prophylaxis with recombinant extended half‐life products (Fc‐rFVIII and Fc‐rFIX) in Ivorian children with hemophilia: Two‐year experience in the 12
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey12
Risk of deep venous thrombosis after total knee arthroplasty in patients with haemophilia A12
Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues11
All‐cause mortality and causes of death in persons with haemophilia: A systematic review and meta‐analysis11
Gynaecological management of women with inherited bleeding disorders. A UK Haemophilia Centres Doctors' Organisation Guideline11
Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France11
The rising incidence of acquired haemophilia A in Germany11
Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis11
3D gait analysis, haemophilia joint health score, leg muscle laterality and biomarkers of joint damage: A cross‐sectional comparative assessment of haemophilic arthropathy11
Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors11
Impact of haemophilia on patients with mild‐to‐moderate disease: Results from the P‐FiQ and B‐HERO‐S studies11
Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey11
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies11
The critical need for postmarketing surveillance in gene therapy for haemophilia11
A case of acquired haemophilia A in a 70‐year‐old post COVID‐19 vaccine11
Assessing the test–retest reliability and smallest detectable change of the Haemophilia Activities List11
Prophylaxis in children with haemophilia in an evolving treatment landscape11
Clinical management of woman with bleeding disorders: A survey among European haemophilia treatment centres11
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis11
Management of comorbidities in haemophilia11
Big picture initiatives in bleeding disorders10
Complications of total knee arthroplasty in patients with haemophilia compared with osteoarthritis and rheumatoid arthritis: A 20‐year single‐surgeon cohort10
Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health10
Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years10
A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen10
Quantitative measurements of haemophilic joint tissues by point‐of‐care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters10
Diagnosis of haemophilia and other inherited bleeding disorders ‐ Is a new paradigm needed?10
Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines10
Validation of a new instrument to measure disease‐related distress among patients with haemophilia10
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with hae10
Abstract10
Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A10
Identification of new F8 deep intronic variations in patients with haemophilia A10
Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC10
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study10
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study10
Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure:9
Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea9
Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL)9
Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders9
Low rate of subclinical venous thrombosis in patients with haemophilia undergoing major orthopaedic surgery in the absence of pharmacological thromboprophylaxis9
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies9
Most subjectively affected joints in patients with haemophilia – what has changed after 20 years in Germany?9
Identified unmet needs and proposed solutions in mild‐to‐moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts9
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes9
Exercise capacity in people with haemophilia: A systematic review9
Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study9
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A9
Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature9
Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders9
Patients’ and parents’ satisfaction with, and preference for, haemophilia A treatments: a cross‐sectional, multicentre, observational study9
Pharmacokinetic‐guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A9
Critical appraisal of the International Prophylaxis Study Group magnetic resonance image scale for evaluating haemophilic arthropathy9
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia9
Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK9
Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy9
Effects of a non‐pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitive‐behavioural therapy associated with physiotherapy9
Promoting physical activity for people with haemophilia in the age of new treatments9
POSTER PRESENTATIONS9
Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A8
Biomarkers of bone disease in persons with haemophilia8
Redefining prophylaxis in the modern era8
Do we need all that emicizumab?8
Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 20228
Haemophilia gene therapy—Update on new country initiatives8
Therapeutic and technological advancements in haemophilia care: Quantum leaps forward8
Severe bleeding in a patient with factor XIII deficiency and COVID‐198
Real‐world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow‐up in a national adult cohort8
An evaluation of PROMIS health domains in adults with haemophilia: A cross‐sectional study8
Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors8
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single‐centre experience8
The effectiveness of manual therapy in addition to passive stretching exercises in the treatment of patients with haemophilic knee arthropathy: A randomized, single‐blind clinical trial8
Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics8
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B‐LONG using haemophilia‐specific quality of life questionnaires8
Effectiveness of emicizumab in preventing life‐threatening bleeding complications in type 3 von Willebrand disease with inhibitors: A paediatric report8
Clinical and patient reported outcome in total ankle replacement compared to ankle fusion in end‐stage haemophilic arthropathy8
Acquired bleeding disorders8
COVID‐19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery8
Towards novel treatment options in von Willebrand disease8
Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset8
Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD‐US system8
Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII‐free emicizumab therapy7
Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China7
Unravelling the knowledge, beliefs, behaviours and concerns of Persons with Haemophilia and their carriers in Senegal7
Patient satisfaction with US Hemophilia Treatment Center Care, Teams and Services: The First National Survey7
The role of total ankle replacement in patients with haemophilia and end‐stage ankle arthropathy: A review7
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Gro7
Thrombomodulin in patients with mild to moderate bleeding tendency7
Adherence to prophylaxis and its association with activation of self‐management and treatment satisfaction7
Successful correction of factor V deficiency of patient‐derived iPSCs by CRISPR/Cas9‐mediated gene editing7
Clinical characteristics and surgical treatment of haemophilic pseudotumor: A retrospective analysis of thirty‐four patients7
Recurrence of a high‐titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis7
A comparison of MyPKFiT and WAPPS‐Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa7
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound7
Pharmacokinetic, efficacy and safety evaluation of B‐domain‐deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A7
Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition7
PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A7
Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary7
Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia7
Depression and anxiety in persons with Von Willebrand disease7
Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline7
Health technology assessment for gene therapies in haemophilia7
Acquired haemophilia A after alemtuzumab therapy7
Single centre, real‐world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery7
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?7
Addressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence‐informed shared decision‐making7
Reimbursing the value of gene therapy care in an era of uncertainty7
Validation of the pictorial blood loss assessment chart using modern sanitary products7
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures7
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma7
Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway6
Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports6
Approximation of emicizumab plasma levels in emergency situations. A practical approach6
Acquired bleeding disorders6
Limited sampling strategies for accurate determination of extended half‐life factor VIII pharmacokinetics in severe haemophilia A patients6
Bleeding with iron deposition and vascular remodelling in subchondral cysts: A newly discovered feature unique to haemophilic arthropathy6
Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy6
Changes in pain profile of patients with haemophilia during 1‐year follow‐up6
Patient and caregiver preferences for haemophilia A treatments: A discrete choice experiment6
Sports participation of patients with haemophilia in the COVID‐19 era: The Dutch experience6
An immediate hypersensitivity reaction induced by PEGylated recombinant factor VIII6
Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study6
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors6
Inhibitors—Recent insights6
Effectiveness of physical exercise on postural balance in patients with haemophilia: A systematic review6
Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis6
Aerobic exercise in patients with haemophilia: A systematic review on safety, feasibility and health effects6
Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A6
Gene therapy – are we ready now?6
Real‐world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes6
Bleeding complications during pregnancy and delivery in haemophilia carriers and their neonates in Western France: An observational study6
Substitution therapy6
Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab6
Pain memories: A new concept to consider in the management of chronic pain in people with haemophilia6
A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures6
Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐90276
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors6
Drug‐associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database6
Severe haemophilia A children on low‐dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on‐demand treatment: A 6‐year follow‐u6
The societal burden of haemophilia A. I – A snapshot of haemophilia A in Australia and beyond6
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B6
The effects of manual therapy on musculoskeletal system, functional level, joint health and kinesiophobia in young adults with severe haemophilia: A randomized pilot study6
Impact of COVID‐19 pandemic on mental health of patients with inherited bleeding disorders in Germany6
Ultrasound and patient self‐imaging in hemophilia6
Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B‐NORD study6
Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)6
Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres6
Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high‐dose bypassing agents in the HAVEN 1 study6
Patient‐reported outcomes in autosomal inherited bleeding disorders: A systematic literature review6
Early wound complications after orthopaedic surgery for haemophilia: What can we do more6
Optimal trough levels in haemophilia B: Raising expectations6
Inhibition of Fenton reaction is a novel mechanism to explain the therapeutic effect of intra‐articular injection of PRP in patients with chronic haemophilic synovitis6
Acupuncture as a therapeutic resource for treatment of chronic pain in people with haemophilia6
Ultrasound and magnetic resonance imaging for the detection of blood: An ex‐vivo study5
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view5
Postpartum haemorrhage in women with mild factor XI deficiency5
Isokinetic knee strength deficit in patients with moderate haemophilia5
0.040578842163086